Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NEXWZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD1yLkCwNFA2OTNizszN M2HqVXNCVkeHUh?=
NCI-H1703 NH[4eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S1S2lEPTB;MD6wNFA6ODJizszN M3PNbHNCVkeHUh?=
KASUMI-1 NUnLdVlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEC2PFIh|ryP MoLzV2FPT0WU
CGTH-W-1 M3rjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1yLkCwO|IzKM7:TR?= NHW1[npUSU6JRWK=
A204 M3v4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnVTWM2OD1yLkCwPVkzKM7:TR?= M{[5TnNCVkeHUh?=
HOP-62 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fzRWlEPTB;MD6xNFg{PiEQvF2= MUjTRW5ITVJ?
H-EMC-SS NXX0VG1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGzSINVUUN3ME2wMlEyODB3IN88US=> NIS2NIxUSU6JRWK=
KU812 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMU[1O|ch|ryP MWrTRW5ITVJ?
EM-2 M3jDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMU[4NVYh|ryP MoTRV2FPT0WU
LAMA-84 NIn1PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\aTWM2OD1yLkG3OlY2KM7:TR?= M2K0VXNCVkeHUh?=
JAR NWTxc21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHYSXAxUUN3ME2wMlI{QTh7IN88US=> MYrTRW5ITVJ?
G-361 NILTPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwM{KzNlUh|ryP NFnNdmJUSU6JRWK=
KG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwM{e2OFIh|ryP NVrvUG8xW0GQR1XS
BV-173 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwM{mzNkDPxE1? MWXTRW5ITVJ?
K5 M4fiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDLe2lKSzVyPUCuOFIyOjdizszN NGPHfFJUSU6JRWK=
MEG-01 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNEKzOlEh|ryP MoC2V2FPT0WU
MFM-223 M4fSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5e2lEPTB;MD60OFc4PiEQvF2= M2rJdnNCVkeHUh?=
BE-13 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\TTWM2OD1yLkWxNFA5KM7:TR?= NWr2Z41qW0GQR1XS
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HSJdKSzVyPUCuO|IyOTNizszN MYHTRW5ITVJ?
SW756 NX\J[HBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzKTWM2OD1yLkm5PFQ3KM7:TR?= NUPVd2dtW0GQR1XS
A2780 M3HkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwMEGxOFYh|ryP M2\4d3NCVkeHUh?=
NB14 NXTj[4FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSzTWM2OD1zLkCxPFAyKM7:TR?= MVrTRW5ITVJ?
H4 NV7mTmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[2THFKSzVyPUGuNFY1OjJizszN M3ezd3NCVkeHUh?=
SK-OV-3 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ziWWlEPTB;MT6wOlY{OyEQvF2= MlTDV2FPT0WU
AN3-CA NWTlc4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CfWlEPTB;MT6wPFM5QSEQvF2= NHjkXGFUSU6JRWK=
A427 NUnYRZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1[WlEPTB;MT6xNFM5OSEQvF2= MYfTRW5ITVJ?
ES7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUGzN|Qh|ryP MVXTRW5ITVJ?
AGS NWTqe49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLOTWM2OD1zLkGxN|k2KM7:TR?= M4[xZnNCVkeHUh?=
G-402 M{e0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWyTWM2OD1zLkG0Olk1KM7:TR?= NEnJPI9USU6JRWK=
ES5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOzTWM2OD1zLkG3NlQ5KM7:TR?= NEC2cY1USU6JRWK=
DEL NYfPSWNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjtW4xKSzVyPUGuNlU1PTdizszN NWj0T3BIW0GQR1XS
NB10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXFcZo3UUN3ME2xMlMzPTV5IN88US=> MljXV2FPT0WU
NCI-H1581 M4jjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1UWlEPTB;MT6zPVA1OiEQvF2= NHvPdWNUSU6JRWK=
D-566MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH1VZdbUUN3ME2xMlQxPjh|IN88US=> MWPTRW5ITVJ?
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLBTWM2OD1zLkSzPVk3KM7:TR?= NGnh[lFUSU6JRWK=
BT-549 NXvBOYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwNU[5NFkh|ryP NFqxWnlUSU6JRWK=
NKM-1 NGPmWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHzTWM2OD1zLk[wOVU3KM7:TR?= NWjq[FI3W0GQR1XS
SW780 Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRW5BKSzVyPUGuOlUyPThizszN MWXTRW5ITVJ?
NCI-H292 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrYOWxKSzVyPUGuOlY{QDNizszN NGTofZZUSU6JRWK=
HMV-II NGnYb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXje45KSzVyPUGuO|A1QDhizszN MmPRV2FPT0WU
ALL-PO NUnZXIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfvSVVKSzVyPUGuPFAxOTVizszN NH\GcohUSU6JRWK=
UACC-257 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwOEKxOlMh|ryP MknFV2FPT0WU
PA-1 NY\m[5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwOEK3NlUh|ryP MWfTRW5ITVJ?
HD-MY-Z NYO0c|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nkXWlEPTB;MT64OlI5OSEQvF2= M1HS[3NCVkeHUh?=
HSC-4 M{HJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO0fJlvUUN3ME2xMlk{QDN7IN88US=> Ml;IV2FPT0WU
GCT MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwMEC5NVYh|ryP NVHqepNKW0GQR1XS
RT-112 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zsN2lEPTB;Mj6xN|QzPCEQvF2= NI\QTYJUSU6JRWK=
A172 M1HS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmSyTWM2OD1{LkGzOlA3KM7:TR?= NEfY[5ZUSU6JRWK=
HCE-T MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMkC1PVgh|ryP M2r5b3NCVkeHUh?=
YH-13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjsTWM2OD1{LkKxOlcyKM7:TR?= NFTaUIZUSU6JRWK=
DK-MG NUnNcpg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwMkO4N|Qh|ryP NUPWRoRsW0GQR1XS
ACN NWD3[W9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwMkO4O|Uh|ryP M4\5dHNCVkeHUh?=
VA-ES-BJ NITGS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLYTWM2OD1{LkK0PVU4KM7:TR?= MXHTRW5ITVJ?
L-363 M33CVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfiV|hKSzVyPUKuNlgxPjFizszN M{GxU3NCVkeHUh?=
HuH-7 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXV[mxHUUN3ME2yMlQzOTZ3IN88US=> M2rXO3NCVkeHUh?=
A4-Fuk NX\iPGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDwd21xUUN3ME2yMlQ4OTZ6IN88US=> MoLBV2FPT0WU
T-24 NX3VWI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwNEiwN|ch|ryP MlixV2FPT0WU
GOTO NVHm[GdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzGSINEUUN3ME2yMlU{ODF|IN88US=> MoHDV2FPT0WU
MV-4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfJ[GdKSzVyPUKuOVkyPjlizszN NXrtTFhXW0GQR1XS
DMS-114 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwNk[zOFUh|ryP M3WyXnNCVkeHUh?=
MHH-NB-11 NYr1cY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonHTWM2OD1{LkewNlk6KM7:TR?= MnnCV2FPT0WU
CHP-212 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjlb4ZKSzVyPUKuPFIxQTFizszN MWPTRW5ITVJ?
DMS-273 NXHwXZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwOUCyNFch|ryP M3HYc3NCVkeHUh?=
SF295 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMEK1PVch|ryP MW\TRW5ITVJ?
NCI-H1563 NYfYWWtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwMUWwNFUh|ryP MUPTRW5ITVJ?
NCI-H446 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme2TWM2OD1|LkKyPFA2KM7:TR?= M{W1OnNCVkeHUh?=
HCC1806 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwMke2OVch|ryP NYDYb2dSW0GQR1XS
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37XSmlEPTB;Mz6zNFAyPyEQvF2= NYDN[3k1W0GQR1XS
SW982 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwM{O4O|Uh|ryP NI\HN5BUSU6JRWK=
ES8 NFHO[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TNWlKSzVyPUOuN|Q6QTlizszN M1vxfnNCVkeHUh?=
SCC-4 NInZ[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPtUIxKSzVyPUOuOVA{QTZizszN NHK5b2xUSU6JRWK=
RPMI-8226 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyOmRKSzVyPUOuOlI3OTZizszN M4HtS3NCVkeHUh?=
EW-11 M1fVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpeGlEPTB;Mz62N|AzOiEQvF2= NGOyS5dUSU6JRWK=
COR-L105 M1;SZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7iTWM2OD1|Lk[zN|M1KM7:TR?= MlLRV2FPT0WU
ES1 M1mxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HJ[GlEPTB;Mz64N|A6PCEQvF2= M3q3RnNCVkeHUh?=
KMOE-2 M3Xncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzyS5NwUUN3ME2zMlkyQDB6IN88US=> NF7uXIFUSU6JRWK=
ABC-1 NEXWOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3YTWM2OD1|LkmzPVEyKM7:TR?= NHLhUGRUSU6JRWK=
NCI-H526 NISy[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi5TWM2OD1|Lkm5NVI3KM7:TR?= NVX1UpBJW0GQR1XS
HCC1395 M2TJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwOUm0PFQh|ryP Ml\TV2FPT0WU
DU-145 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRwMUK4NlUh|ryP NUjiXllnW0GQR1XS
JEG-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrk[m9KSzVyPUSuNVU6OTZizszN M3X0[XNCVkeHUh?=
HCC1187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfYTWM2OD12LkKxOVk4KM7:TR?= NEH0VYVUSU6JRWK=
LC-2-ad M2LFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHPTWM2OD12LkKyNVc4KM7:TR?= M{TPNnNCVkeHUh?=
ONS-76 NUToTJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXTWM2OD12LkK0NVkzKM7:TR?= NWG2[WhDW0GQR1XS
CAL-27 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTHTWM2OD12LkK0N|Q1KM7:TR?= NX\MSJR1W0GQR1XS
8-MG-BA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwMk[2OVgh|ryP NV30S|JEW0GQR1XS
HGC-27 NY[yUndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnhTWM2OD12LkK5OlYh|ryP M1;vT3NCVkeHUh?=
Hs-578-T NWKxempmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwM{G0Olgh|ryP NEHnUXBUSU6JRWK=
EW-1 NHnzeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwNUOwNVQh|ryP MXvTRW5ITVJ?
SW1573 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPlWJFKSzVyPUSuOVUyPjNizszN MnPGV2FPT0WU
SNU-423 NUXkS4duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfOTWM2OD12Lk[wO|kh|ryP NUWxVXhvW0GQR1XS
HOS M1TnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7NWpRKSzVyPUSuOlk4PyEQvF2= NWXIdm5SW0GQR1XS
LB1047-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEPWlEPTB;ND64NVQyQCEQvF2= NWPvWYhvW0GQR1XS
ChaGo-K-1 NWf5cldsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L5XmlEPTB;ND64PVA1QCEQvF2= MXXTRW5ITVJ?
A3-KAW NHH0PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRwOUezOVIh|ryP MkWyV2FPT0WU
CAS-1 M1j5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwOUm5NFgh|ryP MWPTRW5ITVJ?
NBsusSR M3TWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTMW5BKSzVyPUWuNFM2OTRizszN MnXhV2FPT0WU
KM12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkToTWM2OD13LkK5PFI4KM7:TR?= NVjKb2F6W0GQR1XS
NCI-H1155 NGL3SYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTTWM2OD13LkO4NVg2KM7:TR?= NVi0TodyW0GQR1XS
EFM-19 M{T6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PhfmlEPTB;NT60NVc{PyEQvF2= NILJV|BUSU6JRWK=
D-392MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTVwNUe4OFkh|ryP MkPiV2FPT0WU
JVM-3 NWLnNJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTVwN{KzNlUh|ryP NEnteFRUSU6JRWK=
EW-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LXcmlEPTB;NT63OVU5OyEQvF2= M3\pVXNCVkeHUh?=
KARPAS-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HFUmlEPTB;NT64OFMzPSEQvF2= MmDWV2FPT0WU
NCI-H28 NXvxSlFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj3TWM2OD13Lki3PVE5KM7:TR?= MV;TRW5ITVJ?
COLO-829 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7YUmlbUUN3ME21MlkyPTB2IN88US=> MojZV2FPT0WU
KM-H2 NFTnNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;BTGlEPTB;NT65NlM6PSEQvF2= NHfoblVUSU6JRWK=
NCI-H82 NVy3bId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r4RmlEPTB;NT65Nlc4OSEQvF2= NGXXZ45USU6JRWK=
OAW-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zRTWlEPTB;NT65PFgzOSEQvF2= NEe3NFRUSU6JRWK=
A704 NUDo[IdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BTWM2OD14LkGwOVc1KM7:TR?= NGDJdGFUSU6JRWK=
NCI-H1048 M1PKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTc2xKSzVyPU[uNVA2QTlizszN M1vpNXNCVkeHUh?=
LOXIMVI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXrcWh2UUN3ME22MlEyOjR6IN88US=> MkS1V2FPT0WU
MKN45 M{XXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZwMk[wNVYh|ryP NELzeZdUSU6JRWK=
D-502MG MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe1SZdKSzVyPU[uNlg5PTdizszN NFrLfGJUSU6JRWK=
HUTU-80 M3PUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS3eZR2UUN3ME22MlQyPjh6IN88US=> NIjUSlZUSU6JRWK=
S-117 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZwNUCyOlch|ryP Mo\OV2FPT0WU
HCC1569 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TxfGlEPTB;Nj61N|c{PyEQvF2= MoDMV2FPT0WU
J-RT3-T3-5 NVrnV254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonQTWM2OD14LkW0OVczKM7:TR?= NF;vRmhUSU6JRWK=
OC-314 Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHse|BKSzVyPU[uPVEyPTlizszN NYr0TZhuW0GQR1XS
SNU-449 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPqTWM2OD15LkCxNFczKM7:TR?= M37LVnNCVkeHUh?=
NCI-H720 NX3tR5V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwMUmzOFUh|ryP M{nse3NCVkeHUh?=
KP-N-YS NVjBeZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G3SWlEPTB;Nz6yNFczKM7:TR?= NEC1dJNUSU6JRWK=
IGROV-1 M3Xy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvzRmtKSzVyPUeuN|I{QDZizszN MlvGV2FPT0WU
SK-PN-DW MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTdwNEixOUDPxE1? MV7TRW5ITVJ?
HCC1419 NX;hUFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn63TWM2OD15LkWzJO69VQ>? NXm1RXdsW0GQR1XS
HAL-01 NVnEWZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwNkC2OFQh|ryP NWjCUlV4W0GQR1XS
HCC2998 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTdwNkC3OFMh|ryP M1PicXNCVkeHUh?=
SK-N-FI M3eyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IfWlEPTB;Nz62N|A{OyEQvF2= MVzTRW5ITVJ?
GI-ME-N M1zYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HlVmlEPTB;Nz62OFk{PCEQvF2= MU\TRW5ITVJ?
SW1088 NFjac5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzNSItkUUN3ME23MlY2QDJ4IN88US=> NYnpW5A{W0GQR1XS
IA-LM M1H0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmyeGxKSzVyPUeuOlg3OTNizszN MoG4V2FPT0WU
SK-NEP-1 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nYWWlEPTB;Nz62PVYyKM7:TR?= M3nybHNCVkeHUh?=
MDA-MB-415 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSfnJiUUN3ME23Mlg6OTh4IN88US=> MW\TRW5ITVJ?
COLO-800 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW0TWM2OD15Lkm0OFkzKM7:TR?= NXvmbXpLW0GQR1XS
NCI-H2228 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDaN5pGUUN3ME24MlE2Pzh|IN88US=> MkPYV2FPT0WU
D-423MG NYTZRXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3WNmtkUUN3ME24MlIyPzJizszN M3vwV3NCVkeHUh?=
TE-1 NWjJOHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnnTWM2OD16LkS0N|E3KM7:TR?= NFnRdnFUSU6JRWK=
NOS-1 NGX3VIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37KSmlEPTB;OD61NVU{PCEQvF2= MnqzV2FPT0WU
8505C MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ObmlEPTB;OD62OFgzPCEQvF2= MWLTRW5ITVJ?
HEC-1 NFHocJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInldY9KSzVyPUiuO|g1OzlizszN NFHkS2VUSU6JRWK=
TE-11 M3jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\BTGlEPTB;OD65PVU2OSEQvF2= MkjTV2FPT0WU
CTB-1 NVjSdZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTlwMEG0N|Mh|ryP NITQPIxUSU6JRWK=
TGBC11TKB NG\SeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlwMEKyOFEh|ryP NIP3flRUSU6JRWK=
NB17 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq4TWM2OD17LkG4PFch|ryP NIexSoJUSU6JRWK=
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1RZhKSzVyPUmuOFE6PDRizszN NWjXN21lW0GQR1XS
SN12C M2DI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qyTmlEPTB;OT60OVI{PCEQvF2= MnPyV2FPT0WU
COLO-320-HSR MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTlwNkCyN|ch|ryP MmniV2FPT0WU
D-283MED NVzTdosxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zTWM2OD17Lk[zNFczKM7:TR?= M3jhcXNCVkeHUh?=
D-263MG MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfMVlZKSzVyPUmuPFM{QDRizszN NUfRbWhFW0GQR1XS
MEL-JUSO M4ToXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHpW3ZKSzVyPUmuPVAyOjdizszN NHzCXWVUSU6JRWK=
T98G NYjTWGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTlwOUCyNFMh|ryP Mmm5V2FPT0WU
HLE NFH0SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlwOUC5NFkh|ryP Mm\OV2FPT0WU
Ca9-22 NVLobWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzUTWM2OD1zMD6wOlY2KM7:TR?= MUfTRW5ITVJ?
OS-RC-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlTWM2OD1zMD6xNFQ2KM7:TR?= NVj1NodOW0GQR1XS
T47D Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDEPY82UUN3ME2xNE4yPTVizszN MUDTRW5ITVJ?
GI-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1zMD6zOVM{KM7:TR?= MUTTRW5ITVJ?
NUGC-3 NWLqbpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFyLkS0NFIh|ryP NFHQe3NUSU6JRWK=
MDA-MB-361 M3fG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfI[VdKSzVyPUGwMlQ1OzJizszN MnL6V2FPT0WU
SCC-15 NHvCdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ewTWlEPTB;MUCuOFcyQCEQvF2= MXzTRW5ITVJ?
KS-1 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfMTWM2OD1zMD62N|AyKM7:TR?= M{X4N3NCVkeHUh?=
CAL-12T NIeyPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFyLk[zOlEh|ryP M4DoWHNCVkeHUh?=
OVCAR-4 M3i5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnJS3NSUUN3ME2xNE44ODZ6IN88US=> MXnTRW5ITVJ?
HuP-T4 M3ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjZSW9KSzVyPUGxMlA{OjhizszN NH3lU4JUSU6JRWK=
NCI-H358 NVvuZpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXNZoNKSzVyPUGxMlI3PTdizszN MXHTRW5ITVJ?
HO-1-N-1 NX;6fmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfpTWM2OD1zMT6zN|k5KM7:TR?= MYrTRW5ITVJ?
NH-12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXuNnczUUN3ME2xNU42Ozd6IN88US=> MYXTRW5ITVJ?
MOLT-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7pTWM2OD1zMT61PVg2KM7:TR?= M1vjZXNCVkeHUh?=
K-562 NX7YO2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnSN49KSzVyPUGxMlczPDhizszN NF7IWIFUSU6JRWK=
ES6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5cmlEPTB;MUGuPFU5OSEQvF2= NF;4OolUSU6JRWK=
RO82-W-1 NXTRN3RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pTGFKSzVyPUGxMlkxPjRizszN NW\pOpZ4W0GQR1XS
Ramos-2G6-4C10 M3LPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQTWM2OD1zMT65N|Ih|ryP M2[0bXNCVkeHUh?=
23132-87 NXzTPVlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnFPGlKSzVyPUGyMlA5OjFizszN MX7TRW5ITVJ?
A549 MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4TWM2OD1zMj6zNlg2KM7:TR?= MnLHV2FPT0WU
NCI-H23 NUKwd5VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF{LkWwNlYh|ryP MkHEV2FPT0WU
H9 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLaTWM2OD1zMj61OVc4KM7:TR?= NIfDelVUSU6JRWK=
LB771-HNC M4e5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDpfmRKSzVyPUGyMlc3PSEQvF2= NVvTZmt3W0GQR1XS
QIMR-WIL MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF{LkiyOVgh|ryP M3j2UXNCVkeHUh?=
HSC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF{LkmyO|Yh|ryP M2TST3NCVkeHUh?=
PFSK-1 M{TRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;mOGVKSzVyPUGyMlk2ODdizszN MmTlV2FPT0WU
ETK-1 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF|LkC3O|kh|ryP MVfTRW5ITVJ?
SW1710 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV36NlFsUUN3ME2xN{4{PjRzIN88US=> NGrDUmpUSU6JRWK=
COLO-684 NH;TWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3HTWM2OD1zMz60OVQyKM7:TR?= Mln5V2FPT0WU
RPMI-7951 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHCXlJKSzVyPUGzMlUyOzZizszN M{fyOnNCVkeHUh?=
A101D NXnWNHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPtO3UxUUN3ME2xN{42OzR7IN88US=> NI\hcpdUSU6JRWK=
KE-37 NI\4[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhOGlEPTB;MUOuOVg5PyEQvF2= NVnGUWFPW0GQR1XS
SiHa MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vMWGlEPTB;MUOuPFM1PiEQvF2= NUXCXms2W0GQR1XS
NCI-H226 NEXlRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX1O2FKSzVyPUGzMlg5ODhizszN NWL3O4NmW0GQR1XS
DB MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHQWWw{UUN3ME2xN{46QTJ6IN88US=> NHn0VHNUSU6JRWK=
HT-1197 NEHNU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfpTWM2OD1zND6wPFA6KM7:TR?= NILRRZhUSU6JRWK=
SBC-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\hTWM2OD1zND6xN|YzKM7:TR?= NVjZUnJ5W0GQR1XS
VMRC-RCZ M2PU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGyUI5KSzVyPUG0MlU4PzRizszN MXPTRW5ITVJ?
697 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXjTWM2OD1zND62Nlch|ryP MVrTRW5ITVJ?
OMC-1 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGzO5FKSzVyPUG0Mlc5QDhizszN NEPnWIFUSU6JRWK=
SKG-IIIa M{DDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaVm5bUUN3ME2xOE45ODBzIN88US=> M3Lyc3NCVkeHUh?=
DOK Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTtOVIxUUN3ME2xOE46QTN|IN88US=> NHzifGFUSU6JRWK=
NCI-H2029 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF3LkO2NFIh|ryP MmLUV2FPT0WU
NCI-H2009 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0NmlEPTB;MUWuOVA6PSEQvF2= Mln6V2FPT0WU
LK-2 NE\lSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPlTWM2OD1zNT62OFQ6KM7:TR?= NEXVR2tUSU6JRWK=
NCI-H661 M2GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF3LkmwO|Uh|ryP MnKyV2FPT0WU
GT3TKB NFXaVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL4TWM2OD1zNj6wOlc3KM7:TR?= MW\TRW5ITVJ?
GP5d NX63fWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PjWWlEPTB;MU[uN|QzKM7:TR?= Ml7mV2FPT0WU
SK-MEL-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLhTWM2OD1zNj60OFg2KM7:TR?= M1\uWHNCVkeHUh?=
SK-UT-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37NUGlEPTB;MU[uOVY2KM7:TR?= NVW4[lR7W0GQR1XS
NB7 M1LoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XWOWlEPTB;MU[uOlk4OSEQvF2= M4LXbnNCVkeHUh?=
NCI-H460 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfPZ5hKSzVyPUG2Mlc{OjZizszN NHjsXm1USU6JRWK=
8305C NUjYXGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\tTWM2OD1zNj63PFc4KM7:TR?= M4TTeHNCVkeHUh?=
CaR-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD1zNj64NVEyKM7:TR?= M3jmXHNCVkeHUh?=
D-247MG Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnkcm1FUUN3ME2xOk45PjJ3IN88US=> MlXaV2FPT0WU
LoVo NFu3PGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpT2lEPTB;MU[uPVQ5QCEQvF2= M1v1eHNCVkeHUh?=
NCI-H2405 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ncmlEPTB;MUeuNVkxQCEQvF2= MlPvV2FPT0WU
AU565 M1;NOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TrZmlEPTB;MUeuNlI2KM7:TR?= NYPCO2s1W0GQR1XS
OCI-AML2 M{DtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzTbZdKSzVyPUG3MlU{OTdizszN NYf5Rm5HW0GQR1XS
22RV1 NW\DfG05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G2TmlEPTB;MUeuOVg5PCEQvF2= MY\TRW5ITVJ?
HT-144 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT5TWM2OD1zNz62OVk5KM7:TR?= MXzTRW5ITVJ?
HuO9 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF5LkewN|Eh|ryP M3;ncnNCVkeHUh?=
Daoy NELMZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF5LkexPFQh|ryP MXzTRW5ITVJ?
SJRH30 NGjTSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO0NnZ[UUN3ME2xO{45PDh7IN88US=> MlzsV2FPT0WU
CHL-1 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThd5lMUUN3ME2xO{46OjR7IN88US=> MXjTRW5ITVJ?
J82 NGftVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHFVoVXUUN3ME2xO{46PjN3IN88US=> MVnTRW5ITVJ?
COR-L23 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPPTWM2OD1zOD6wNFEyKM7:TR?= MlPHV2FPT0WU
SNU-C2B MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF6LkKyO|Yh|ryP MUTTRW5ITVJ?
NCI-H1770 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnyTWM2OD1zOD60OlE2KM7:TR?= M4\sfnNCVkeHUh?=
MHH-PREB-1 M2PK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF6LkW2PVch|ryP M3zMcXNCVkeHUh?=
ES3 M2TQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[zfFhKSzVyPUG4MlU5QDNizszN NGrxRnpUSU6JRWK=
MDA-MB-231 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjxd3RvUUN3ME2xPE43PTB{IN88US=> NX7CXHhCW0GQR1XS
MN-60 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTrTWM2OD1zOT6wOVkzKM7:TR?= Mni5V2FPT0WU
EPLC-272H MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPpTolIUUN3ME2xPU4{PzB6IN88US=> NGHqcoxUSU6JRWK=
SW948 NWH1SppPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRbWlEPTB;MUmuN|k{PCEQvF2= MUjTRW5ITVJ?
MOLT-13 NFfDbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPsTWM2OD1zOT60OVQ3KM7:TR?= NWPRcXpRW0GQR1XS
HL-60 NGDpblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED2PGlKSzVyPUKwMlIyPDFizszN NYPVV3BvW0GQR1XS
CP50-MEL-B NFW4PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJyLkS3OFgh|ryP M1nlWHNCVkeHUh?=
NTERA-S-cl-D1 M4Tze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyLkS5O|gh|ryP M{DZeXNCVkeHUh?=
KINGS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPRSWNQUUN3ME2yNE44QTZ5IN88US=> MojiV2FPT0WU
DOHH-2 NUfSO4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED1WJdKSzVyPUKwMlkxPiEQvF2= NFf2UJRUSU6JRWK=
BB65-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJyLkmyPFUh|ryP NX7sPVJNW0GQR1XS
NB12 NV\JPHJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoizTWM2OD1{MT6wN|k1KM7:TR?= NXHReFFjW0GQR1XS
KY821 NV25XnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O4TGlEPTB;MkGuOVgzKM7:TR?= M2S5e3NCVkeHUh?=
PSN1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJzLk[0OVMh|ryP NV7p[Yc6W0GQR1XS
EGI-1 M1nBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJzLke0OVQh|ryP NWnlPHpxW0GQR1XS
CTV-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ{LkOwN|Eh|ryP MVLTRW5ITVJ?
TI-73 NXXUW5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u2VWlEPTB;MkKuN|Q6QCEQvF2= NX35fWdqW0GQR1XS
LCLC-103H M{nYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ{LkS3OVIh|ryP NVi5ZYdiW0GQR1XS
D-542MG MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzkVGttUUN3ME2yNk42PTV6IN88US=> NW\SXlVwW0GQR1XS
ATN-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MTWlEPTB;MkKuOlQ{QSEQvF2= MYjTRW5ITVJ?
SK-MEL-1 NVL0ZnlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ{LkizOlgh|ryP MYnTRW5ITVJ?
HDLM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1{Mz6xOFc5KM7:TR?= M{\xdXNCVkeHUh?=
UM-UC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTHSlFNUUN3ME2yN{4yQTR2IN88US=> M3nkXXNCVkeHUh?=
NCI-H1573 NFvCOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPxOpZKSzVyPUKzMlQ3QDFizszN NHrJZlBUSU6JRWK=
NCI-H520 NH[z[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ|LkS5OFgh|ryP NGj2SIhUSU6JRWK=
ESS-1 NIP2UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml20TWM2OD1{Mz64NFU6KM7:TR?= NGrw[4lUSU6JRWK=
COR-L88 M3W4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXaTWM2OD1{Mz65OFc2KM7:TR?= MoDrV2FPT0WU
TGBC24TKB M1frfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7iTWM2OD1{ND6wN|EzKM7:TR?= NHnTOYFUSU6JRWK=
HCC1937 NWXYTm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LwZWlEPTB;MkSuNUDPxE1? NFLEPJhUSU6JRWK=
RS4-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuz[IdQUUN3ME2yOE4yPDJizszN NXvxeXZiW0GQR1XS
HCC38 NYDBNmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ2LkKzPVQh|ryP MWTTRW5ITVJ?
RPMI-2650 NVrvTG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\QTWlEPTB;MkSuOlE3OiEQvF2= MVLTRW5ITVJ?
P12-ICHIKAWA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\zVGlEPTB;MkSuOlI2QCEQvF2= NF7aTWhUSU6JRWK=
YAPC NGnjdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7kSJZKSzVyPUK0MlgzOTRizszN MUDTRW5ITVJ?
NB13 NX;MR2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ3LkK2NVEh|ryP NV\NT4xKW0GQR1XS
SK-N-AS NXfKbJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofyTWM2OD1{NT64OVg1KM7:TR?= NVvkb|YyW0GQR1XS
SK-N-DZ NGPyb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\3cXVtUUN3ME2yOk4xPDlizszN NFGzfG5USU6JRWK=
LS-411N MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HNXWlEPTB;Mk[uNlA{QCEQvF2= NF7HUWhUSU6JRWK=
NCI-H810 NWPyNpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ4LkOxNVIh|ryP M17XcHNCVkeHUh?=
NCI-SNU-1 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn6TWM2OD1{Nj61OFU1KM7:TR?= MXfTRW5ITVJ?
HH MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvrUG5KSzVyPUK2MlU2OjlizszN NEn3eHdUSU6JRWK=
U-2-OS NIr3[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Kc5hKSzVyPUK2Mlc{QDJizszN MkO5V2FPT0WU
SF539 NYXHUJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzXUZFKSzVyPUK2MlgxOThizszN M4XUUHNCVkeHUh?=
NCI-H2052 NFeyWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ5LkC4OkDPxE1? NVLIXJVKW0GQR1XS
A673 NXXwNXplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ5LkKxNFIh|ryP NFfWeIJUSU6JRWK=
WM-115 NI\DeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe5[pNKSzVyPUK3Mlc4PjdizszN NF;LU2VUSU6JRWK=
SW48 M2rOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ5LkiwNFUh|ryP NX7peGlQW0GQR1XS
NOMO-1 NFr1WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTMTWM2OD1{Nz64OVMzKM7:TR?= MWDTRW5ITVJ?
PC-3 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ5Lki5OFEh|ryP NYHJZYJ5W0GQR1XS
UMC-11 M2PnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG3Z5pKSzVyPUK3Mlk{PDNizszN M2DWU3NCVkeHUh?=
U-118-MG MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ6LkCxNlMh|ryP M{LGcHNCVkeHUh?=
NCI-H2452 NGjHPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ6LkC4NlIh|ryP M2XS[HNCVkeHUh?=
CAMA-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ6Lki1OlQh|ryP M4fqSXNCVkeHUh?=
MC-IXC NWfPXodbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjBW3lKSzVyPUK5MlI{PjZizszN NWDEcYNXW0GQR1XS
ES4 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXp[ZRWUUN3ME2yPU4{OTd{IN88US=> M4[2O3NCVkeHUh?=
BHT-101 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj6TWM2OD1{OT6zNlEh|ryP NInGRolUSU6JRWK=
KP-4 NIfmbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnXNGVKSzVyPUK5MlUyPiEQvF2= MVnTRW5ITVJ?
CAL-54 NVTCPXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzmV5lKSzVyPUK5MlU1PDVizszN MlnXV2FPT0WU
5637 NGCyXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ7Lk[0NlEh|ryP MmT1V2FPT0WU
MOLT-16 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT3eHJKSzVyPUK5MlczPjlizszN NFLIOlBUSU6JRWK=
Ca-Ski NUP3cIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVywbVk4UUN3ME2yPU46PDZizszN M{LuUXNCVkeHUh?=
AsPC-1 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNyLkCyNVIh|ryP NHzhNnBUSU6JRWK=
MSTO-211H NWHaU4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X6eWlEPTB;M{CuNVUh|ryP MmLWV2FPT0WU
L-428 NFXTN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNyLkSwOUDPxE1? M3qwNnNCVkeHUh?=
SW1463 NHH3VYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfyUll{UUN3ME2zNE42Ozh|IN88US=> M4n1RnNCVkeHUh?=
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNyLkW1O|Qh|ryP NF\LOXZUSU6JRWK=
CAKI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPNWIY5UUN3ME2zNE44PzB{IN88US=> MmrRV2FPT0WU
YKG-1 M4O0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0R2lEPTB;M{GuNFI3OyEQvF2= NHq3NmZUSU6JRWK=
A2058 NHLIUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNzLkGxOlQh|ryP M3LtTnNCVkeHUh?=
A375 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTiXFNCUUN3ME2zNU4yPjl4IN88US=> MVfTRW5ITVJ?
SNB75 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPcWlEPTB;M{GuNlQ{PSEQvF2= NF7U[JhUSU6JRWK=
SK-HEP-1 NIO1XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rBcWlEPTB;M{GuOFI4OSEQvF2= MmnRV2FPT0WU
ME-180 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNzLk[1OFIh|ryP MkfzV2FPT0WU
NCI-H209 NFK0bZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRc4pKSzVyPUOxMlgzPDdizszN M{HsVHNCVkeHUh?=
HC-1 M{P4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjOPFVPUUN3ME2zNk4yPDR4IN88US=> NUfjcnp2W0GQR1XS
LB373-MEL-D MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljjTWM2OD1|Mj6xPVcyKM7:TR?= MYPTRW5ITVJ?
SNU-387 NF;RNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jR[WlEPTB;M{KuN|E6OSEQvF2= M{HRZXNCVkeHUh?=
C32 NFX2ZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN{LkOzOVMh|ryP MkTxV2FPT0WU
EW-13 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN{Lkm0NFgh|ryP M2HPbHNCVkeHUh?=
BFTC-905 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1|Mz61NVM3KM7:TR?= NWCxR2JwW0GQR1XS
NCI-H1299 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN|LkW2NlEh|ryP NYLFcGlSW0GQR1XS
LU-135 NI\GRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\xVGlEPTB;M{OuPFAyKM7:TR?= M1rt[HNCVkeHUh?=
NCI-H2122 NIfpNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXVc29KSzVyPUOzMlk6PjZizszN MoPTV2FPT0WU
SK-LMS-1 NEPNVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T3cGlEPTB;M{SuOFExPyEQvF2= NGnaNo9USU6JRWK=
LNCaP-Clone-FGC NHHZdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHwTWM2OD1|ND64OVE2KM7:TR?= M3\3NHNCVkeHUh?=
NCI-H1092 M3HQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQNIhoUUN3ME2zOU4zPzR5IN88US=> NHvQVI9USU6JRWK=
MS-1 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN3LkOwN|gh|ryP MlLTV2FPT0WU
KYSE-510 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKxWpV[UUN3ME2zOU42ODR{IN88US=> MmDJV2FPT0WU
NCI-H1793 NXnsT4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fUdmlEPTB;M{WuOlU1PSEQvF2= NFXzU|dUSU6JRWK=
MIA-PaCa-2 NGrwS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GyemlEPTB;M{[uNFQ6PiEQvF2= Mny0V2FPT0WU
EW-22 NV[2cXJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHMW4xMUUN3ME2zOk41ODd{IN88US=> M2PGWnNCVkeHUh?=
IGR-1 NXy1UHp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHVItKSzVyPUO2MlgyQDRizszN MmLIV2FPT0WU
HT-1080 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XmXGlEPTB;M{euNVI2KM7:TR?= MlXOV2FPT0WU
M14 NWDpTVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv6TWM2OD1|Nz6xOlQzKM7:TR?= NXfFUIpJW0GQR1XS
786-0 NWfSVZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XuZmlEPTB;M{euNlc6PCEQvF2= NXnBOmRtW0GQR1XS
MZ2-MEL NHG5XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjvSIlKSzVyPUO3MlQ2ODFizszN MlT0V2FPT0WU
NCI-H510A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXITWM2OD1|Nz65OFEzKM7:TR?= MX\TRW5ITVJ?
LAN-6 NUfWfnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPnXopUUUN3ME2zO{46PTh{IN88US=> MVjTRW5ITVJ?
SW620 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZPWRKSzVyPUO4MlQ6PzRizszN MWTTRW5ITVJ?
LB2241-RCC NWW5fpdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT0[XBZUUN3ME2zPU45OjB3IN88US=> M{K2O3NCVkeHUh?=
Detroit562 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLS2lEPTB;NECuNVI3QCEQvF2= MWHTRW5ITVJ?
HN NHywSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfJUVFKSzVyPUSwMlE4QDJizszN M{TiNXNCVkeHUh?=
HCT-15 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76fYY{UUN3ME20NE42QTB5IN88US=> M3\3cnNCVkeHUh?=
C2BBe1 NIHuZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiSFVKSzVyPUSwMlkyPTdizszN M{P1NnNCVkeHUh?=
A498 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknlTWM2OD12MT6zNFE2KM7:TR?= NXzqcWV5W0GQR1XS
SK-MEL-24 NEf5b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GTXRuUUN3ME20NU41PzJ3IN88US=> MYjTRW5ITVJ?
OVCAR-5 M3LNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvbGVRUUN3ME20NU44PzZ5IN88US=> MWnTRW5ITVJ?
NCI-H1792 NVHKPIVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\XZmlEPTB;NEGuPVgzOSEQvF2= NVjNUnBTW0GQR1XS
KOSC-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPFNHZSUUN3ME20Nk4zPjl7IN88US=> M3TEUXNCVkeHUh?=
Mo-T MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[3TWM2OD12Mj64PVU5KM7:TR?= M{jTd3NCVkeHUh?=
CFPAC-1 M1jRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX5bXJKSzVyPUSzMlQ6PDRizszN MknSV2FPT0WU
CAL-51 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Tv[mlEPTB;NEOuOVYxPSEQvF2= MXzTRW5ITVJ?
RH-18 NX24dYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR|LkiwOUDPxE1? NYLyWpd5W0GQR1XS
EC-GI-10 M{Px[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Bc49KSzVyPUSzMlg{PDdizszN MlLlV2FPT0WU
HSC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XxTWlEPTB;NESuNFA6KM7:TR?= NUj1N2syW0GQR1XS
ML-2 NVK3cph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PSdmlEPTB;NEWuNlYzOSEQvF2= M{PSc3NCVkeHUh?=
KNS-81-FD MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fTbGlEPTB;NEWuO|M3PSEQvF2= MWrTRW5ITVJ?
NB6 NFv5dXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD12Nj6xNVEh|ryP NEfNNVNUSU6JRWK=
MCF7 NXPScVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf0TWM2OD12Nj61OVM{KM7:TR?= MoLCV2FPT0WU
P30-OHK MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD12Nj64NVE4KM7:TR?= NXj6[JBuW0GQR1XS
BPH-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zIVWlEPTB;NE[uPVgxPSEQvF2= MYnTRW5ITVJ?
U251 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zmcmlEPTB;NE[uPVk1KM7:TR?= MmjoV2FPT0WU
MKN1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR5LkWxN|ch|ryP M1jWV3NCVkeHUh?=
A431 M2PlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rRfmlEPTB;NEeuPFM{QCEQvF2= MkX2V2FPT0WU
C8166 NVLnfnZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzRTWM2OD12OT6yNFM6KM7:TR?= Mn7RV2FPT0WU
HEL M4HxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC2[Io4UUN3ME20PU41ODZ2IN88US=> MmXvV2FPT0WU
RMG-I Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXyWnpKSzVyPUS5MlQ1PDRizszN Mnq2V2FPT0WU
CAL-72 NFLwdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTR7Lk[wO|Uh|ryP NH[3VXlUSU6JRWK=
SW962 NHnrbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR7LkmzN|Ih|ryP MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% CMC 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID